Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.52 |
| ▸ | ASAH1 | Q13510 | 1/20 | 0.52 |
| ▸ | SQOR | Q9Y6N5 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.44 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.44 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.44 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.44 |
| ▸ | GRIK5 | Q16478 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.42 |
| ▸ | HBB | P68871 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetic Acid SCHEMBL28372215 | 0.82 | LMNA (0.48) | LMNASMN1; SMN2CYP3A4CYP2D6MAPK3 | |
| SCHEMBL7764701 | 0.82 | LMNA (0.48) | LMNASMN1; SMN2CYP3A4CYP2D6MAPK3 | |
| SCHEMBL11741360 | 0.81 | LMNA (0.61) | LMNASMN1; SMN2CYP3A4CYP2D6MAPK3 | |
| SCHEMBL7915827 | 0.81 | LMNA (0.49) | LMNASMN1; SMN2CYP3A4CYP2D6MAPK3 | |
| SCHEMBL7540032 | 0.81 | LMNA (0.49) | LMNASMN1; SMN2CYP3A4CYP2D6MAPK3 | |
| SCHEMBL11739898 | 0.80 | LMNA (0.49) | LMNASMN1; SMN2CYP3A4CYP2D6MAPK3 | |
| SCHEMBL6713750 | 0.78 | MAPK1 (0.42) | LMNA | |
| SCHEMBL10459087 | 0.78 | ASAH1 (0.72) | LMNASMN1; SMN2CYP3A4CYP2D6MAPK3 | |
| SCHEMBL11024545 | 0.78 | LMNA (0.61) | LMNASMN1; SMN2CYP3A4CYP2D6MAPK3 | |
| SCHEMBL11092234 | 0.78 | LMNA (0.57) | LMNASMN1; SMN2CYP3A4CYP2D6MAPK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-57024369-A | — | — | None | — | — | JP | disclosed |
| US-20250302995-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | SHIVALILA CHIKDU SHAKTI (US) | 2025-10-02 | — | — | US | disclosed |
| US-20250262235-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS RELATING THERETO | WAVE LIFE SCIENCES LTD (SG) | 2025-08-21 | — | — | US | disclosed |
| US-20250135036-A1 | COMPOSITIONS FOR EDITING MECP2 TRANSCRIPTS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2025-05-01 | — | — | US | disclosed |
| EP-4522744-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | Wave Life Sciences Ltd. (SG) | 2025-03-19 | — | — | EP | disclosed |
| EP-4507700-A2 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS RELATING THERETO | Wave Life Sciences Ltd. (SG) | 2025-02-19 | — | — | EP | disclosed |
| CN-119452084-A | Oligonucleotide compositions and methods thereof | 波涛生命科学有限公司 | 2025-02-14 | — | — | CN | disclosed |
| CN-119317632-A | Oligonucleotide compositions and methods relating thereto | 波涛生命科学有限公司 | 2025-01-14 | — | — | CN | disclosed |
| EP-4404942-A2 | COMPOSITIONS FOR EDITING MECP2 TRANSCRIPTS AND METHODS THEREOF | Wave Life Sciences Ltd. (SG) | 2024-07-31 | — | — | EP | disclosed |
| WO-2023220428-A1 | COMPOSITIONS FOR EDITING ASS1 TRANSCRIPTS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2023-11-16 | — | — | WO | disclosed |
| WO-2023201095-A2 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS RELATING THERETO | WAVE LIFE SCIENCES LTD. (SG) | 2023-10-19 | — | — | WO | disclosed |
| WO-2023049477-A2 | COMPOSITIONS FOR EDITING MECP2 TRANSCRIPTS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2023-03-30 | — | — | WO | disclosed |
| EP-0265506-A1 | A PRODRUG FORM OF 5-FLUOROURACIL AND A METHOD OF TREATMENT OF CANCER | FARMACEUTISK LABORATORIUM FERRING A/S (DK) | 1988-05-04 | — | — | EP | disclosed |
| WO-1987006581-A1 | A PRODRUG FORM OF 5-FLUOROURACIL AND A METHOD OF TREATMENT OF CANCER | FARMACEUTISK LABORATORIUM FERRING A/S (DK) | 1987-11-05 | — | — | WO | disclosed |
| US-4528372-A | N-Phthalidyl-5-fluorouracils | GRELAN PHARMACEUTICAL CO., LTD. (JP) | 1985-07-09 | — | — | US | disclosed |
| EP-0062068-B1 | N-PHTHALIDYL-5-FLUOROURACIL DERIVATIVES | GRELAN PHARMACEUTICAL CO., LTD. (JP) | 1985-06-12 | — | — | EP | disclosed |
| EP-0062068-A1 | N-PHTHALIDYL-5-FLUOROURACIL DERIVATIVES | GRELAN PHARMACEUTICAL CO., LTD. (JP) | 1982-10-13 | — | — | EP | disclosed |
| JP-S5724369-A | PYRIMIDINE DERIVATIVE AND ITS PREPARATION | TOKYO KINZOKU KOGYO KK | 1982-02-08 | — | — | JP | disclosed |
| WO-1979000922-A1 | URACIL DERIVATIVES,PROCESS FOR PREPARING THE SAME,AND ONCOTIC PREPARATION THEREOF | OKADA T | 1979-11-15 | — | — | WO | disclosed |
| US-4088646-A | ANTITUMOR AND ANTICARCINOGENIC AGENTS | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JA) | 1978-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250302995-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | ADAR, NSUN2, RNGTT | LMNA 793/4885SMN1; SMN2 218/4885CYP3A4 4641/4885 |
| US-20250262235-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS RELATING THERETO | ADAR, RNGTT, NSUN2 | LMNA 1350/4885SMN1; SMN2 292/4885CYP3A4 4584/4885 |
| US-20250135036-A1 | COMPOSITIONS FOR EDITING MECP2 TRANSCRIPTS AND METHODS THEREOF | MECP2, ADAR, NSUN2 | LMNA 653/4885SMN1; SMN2 74/4885CYP3A4 4882/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.